S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Stock market today: World markets are mixed and Japan's Nikkei tops 40,000, on eve of China congress
Critical asset just had biggest fall on record (Ad)
China seeks ways to revive slowing economy and salvage property market as annual congress convenes
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Stock market today: World markets are mixed and Japan's Nikkei tops 40,000, on eve of China congress
Critical asset just had biggest fall on record (Ad)
China seeks ways to revive slowing economy and salvage property market as annual congress convenes
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Stock market today: World markets are mixed and Japan's Nikkei tops 40,000, on eve of China congress
Critical asset just had biggest fall on record (Ad)
China seeks ways to revive slowing economy and salvage property market as annual congress convenes
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Stock market today: World markets are mixed and Japan's Nikkei tops 40,000, on eve of China congress
Critical asset just had biggest fall on record (Ad)
China seeks ways to revive slowing economy and salvage property market as annual congress convenes
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts

Agile Therapeutics (AGRX) Competitors

$0.85
+0.06 (+6.92%)
(As of 03/1/2024 08:51 PM ET)

AGRX vs. PHIO, CPHI, ENVB, CYCC, SNOA, SLRX, CWBR, QLGN, EVOK, and ATXI

Should you be buying Agile Therapeutics stock or one of its competitors? The main competitors of Agile Therapeutics include Phio Pharmaceuticals (PHIO), China Pharma (CPHI), Enveric Biosciences (ENVB), Cyclacel Pharmaceuticals (CYCC), Sonoma Pharmaceuticals (SNOA), Salarius Pharmaceuticals (SLRX), CohBar (CWBR), Qualigen Therapeutics (QLGN), Evoke Pharma (EVOK), and Avenue Therapeutics (ATXI). These companies are all part of the "pharmaceutical preparations" industry.

Agile Therapeutics vs.

Agile Therapeutics (NASDAQ:AGRX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Agile Therapeutics. MarketBeat recorded 3 mentions for Phio Pharmaceuticals and 2 mentions for Agile Therapeutics. Phio Pharmaceuticals' average media sentiment score of 0.62 beat Agile Therapeutics' score of 0.43 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Agile Therapeutics Neutral
Phio Pharmaceuticals Positive

Agile Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Agile Therapeutics received 389 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. Likewise, 68.28% of users gave Agile Therapeutics an outperform vote while only 62.50% of users gave Phio Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Agile TherapeuticsOutperform Votes
424
68.28%
Underperform Votes
197
31.72%
Phio PharmaceuticalsOutperform Votes
35
62.50%
Underperform Votes
21
37.50%

Phio Pharmaceuticals has a net margin of 0.00% compared to Agile Therapeutics' net margin of -69.73%. Agile Therapeutics' return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Agile Therapeutics-69.73% N/A -188.07%
Phio Pharmaceuticals N/A -132.45%-105.30%

Phio Pharmaceuticals has lower revenue, but higher earnings than Agile Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agile Therapeutics$10.88M0.23-$25.41M-$13.33-0.06
Phio PharmaceuticalsN/AN/A-$11.48MN/AN/A

7.5% of Agile Therapeutics shares are owned by institutional investors. Comparatively, 12.4% of Phio Pharmaceuticals shares are owned by institutional investors. 0.5% of Agile Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Agile Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 900.00%. Phio Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 317.45%. Given Agile Therapeutics' higher possible upside, equities analysts plainly believe Agile Therapeutics is more favorable than Phio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agile Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Phio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Agile Therapeutics and Phio Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.


Get Agile Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGRX vs. The Competition

MetricAgile TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.52M$6.59B$4.77B$7.57B
Dividend YieldN/A2.83%5.36%3.87%
P/E Ratio-0.067.06189.1615.27
Price / Sales0.23230.872,969.9780.58
Price / CashN/A19.6533.9428.85
Price / Book-0.124.974.564.67
Net Income-$25.41M$149.43M$108.85M$208.47M
7 Day Performance5.17%8.01%115.37%3.63%
1 Month Performance-42.18%19.35%127.26%9.16%
1 Year Performance252.70%9.46%133.74%8.30%

Agile Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHIO
Phio Pharmaceuticals
2.8638 of 5 stars
$0.96
+3.2%
$4.00
+317.8%
-84.0%$2.34MN/A0.009
CPHI
China Pharma
0 of 5 stars
$0.07
-12.2%
N/AN/A$2.37M$8.10M0.00234Analyst Report
Stock Split
Gap Down
ENVB
Enveric Biosciences
2.4813 of 5 stars
$0.84
-1.2%
$10.00
+1,090.5%
-14.4%$2.30MN/A-0.0725Gap Up
CYCC
Cyclacel Pharmaceuticals
2.9455 of 5 stars
$2.72
-2.9%
$70.50
+2,491.9%
-74.9%$2.29MN/A-0.092,018Short Interest ↓
Gap Down
SNOA
Sonoma Pharmaceuticals
3.2907 of 5 stars
$0.15
flat
$3.25
+2,119.9%
-86.3%$2.29M$13.27M-0.159Short Interest ↓
News Coverage
SLRX
Salarius Pharmaceuticals
1.0405 of 5 stars
$0.62
+3.3%
N/A-69.6%$2.44M$1.84M-0.0912Short Interest ↓
Gap Down
CWBR
CohBar
0 of 5 stars
$0.76
-13.6%
N/A-58.5%$2.21MN/A-0.179Upcoming Earnings
Gap Down
QLGN
Qualigen Therapeutics
0.7426 of 5 stars
$0.49
-15.5%
N/A-60.8%$2.54M$4.98M0.0031High Trading Volume
EVOK
Evoke Pharma
0 of 5 stars
$0.63
flat
N/A-77.8%$2.11M$2.51M-0.284Analyst Report
Gap Up
ATXI
Avenue Therapeutics
4.0935 of 5 stars
$0.15
+6.9%
$32.00
+20,612.0%
-85.1%$2.05MN/A-0.262Gap Down

Related Companies and Tools

This page (NASDAQ:AGRX) was last updated on 3/4/2024 by MarketBeat.com Staff